These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 11063589)

  • 1. Critical role of a subdomain of the N-terminus of the V1a vasopressin receptor for binding agonists but not antagonists; functional rescue by the oxytocin receptor N-terminus.
    Hawtin SR; Wesley VJ; Parslow RA; Patel S; Wheatley M
    Biochemistry; 2000 Nov; 39(44):13524-33. PubMed ID: 11063589
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Agonist-specific, high-affinity binding epitopes are contributed by an arginine in the N-terminus of the human oxytocin receptor.
    Wesley VJ; Hawtin SR; Howard HC; Wheatley M
    Biochemistry; 2002 Apr; 41(16):5086-92. PubMed ID: 11955056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of an extracellular segment of the oxytocin receptor providing agonist-specific binding epitopes.
    Hawtin SR; Howard HC; Wheatley M
    Biochem J; 2001 Mar; 354(Pt 2):465-72. PubMed ID: 11171127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single residue (arg46) located within the N-terminus of the V1a vasopressin receptor is critical for binding vasopressin but not peptide or nonpeptide antagonists.
    Hawtin SR; Wesley VJ; Parslow RA; Simms J; Miles A; McEwan K; Wheatley M
    Mol Endocrinol; 2002 Mar; 16(3):600-9. PubMed ID: 11875119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Agonist binding to peptide hormone receptors.
    Wheatley M; Hawtin SR; Wesley VJ; Howard HC; Simms J; Miles A; McEwan K; Parslow RA
    Biochem Soc Trans; 2003 Feb; 31(Pt 1):35-9. PubMed ID: 12546649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of neurohypophysial hormone receptor domains involved in ligand binding and G protein coupling.
    Postina R; Kojro E; Fahrenholz F
    Adv Exp Med Biol; 1998; 449():371-85. PubMed ID: 10026828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M; Stoev S; Chini B; Durroux T; Mouillac B; Guillon G
    Prog Brain Res; 2008; 170():473-512. PubMed ID: 18655903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of YM218, a nonpeptide vasopressin V1A receptor-selective antagonist, on human vasopressin and oxytocin receptors.
    Tahara A; Tsukada J; Tomura Y; Kusayama T; Wada K; Ishii N; Taniguchi N; Suzuki T; Yatsu T; Uchida W; Shibasaki M
    Pharmacol Res; 2005 Mar; 51(3):275-81. PubMed ID: 15661579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular pharmacology of human vasopressin receptors.
    Thibonnier M; Conarty DM; Preston JA; Wilkins PL; Berti-Mattera LN; Mattera R
    Adv Exp Med Biol; 1998; 449():251-76. PubMed ID: 10026814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The N-terminal juxtamembrane segment of the V1a vasopressin receptor provides two independent epitopes required for high-affinity agonist binding and signaling.
    Hawtin SR; Wesley VJ; Simms J; Argent CC; Latif K; Wheatley M
    Mol Endocrinol; 2005 Nov; 19(11):2871-81. PubMed ID: 15994199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selective blockade of oxytocin and vasopressin V(1a) receptors in anaesthetised rats: evidence that activation of oxytocin receptors rather than V(1a) receptors increases sodium excretion.
    Shirley DG; Walter MF; Keeler BD; Waters NJ; Walter SJ
    Nephron Physiol; 2011; 117(3):p21-6. PubMed ID: 21071981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological characterization of FE 202158, a novel, potent, selective, and short-acting peptidic vasopressin V1a receptor full agonist for the treatment of vasodilatory hypotension.
    Laporte R; Kohan A; Heitzmann J; Wisniewska H; Toy J; La E; Tariga H; Alagarsamy S; Ly B; Dykert J; Qi S; Wisniewski K; Galyean R; Croston G; Schteingart CD; Rivière PJ
    J Pharmacol Exp Ther; 2011 Jun; 337(3):786-96. PubMed ID: 21411496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor.
    Thibonnier M; Auzan C; Madhun Z; Wilkins P; Berti-Mattera L; Clauser E
    J Biol Chem; 1994 Feb; 269(5):3304-10. PubMed ID: 8106369
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis for agonist selectivity in the vasopressin/oxytocin receptor family.
    Chini B; Mouillac B; Ala Y; Balestre MN; Cotte N; Trumpp-Kallmeyer S; Hoflack J; Elands J; Hibert M; Manning M
    Adv Exp Med Biol; 1995; 395():321-8. PubMed ID: 8713982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amino acids in the COOH-terminal region of the oxytocin receptor third intracellular domain are important for receptor function.
    Zhong M; Parish B; Murtazina DA; Ku CY; Sanborn BM
    Am J Physiol Endocrinol Metab; 2007 Apr; 292(4):E977-84. PubMed ID: 17148753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An arginyl in the N-terminus of the V1a vasopressin receptor is part of the conformational switch controlling activation by agonist.
    Hawtin SR; Wesley VJ; Simms J; Parslow RA; Miles A; McEwan K; Keen M; Wheatley M
    Eur J Biochem; 2003 Dec; 270(23):4681-8. PubMed ID: 14622255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4.
    Cheng LL; Stoev S; Manning M; Derick S; Pena A; Mimoun MB; Guillon G
    J Med Chem; 2004 Apr; 47(9):2375-88. PubMed ID: 15084136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic interaction of human vasopressin/oxytocin receptor subtypes with G protein-coupled receptor kinases and protein kinase C after agonist stimulation.
    Berrada K; Plesnicher CL; Luo X; Thibonnier M
    J Biol Chem; 2000 Sep; 275(35):27229-37. PubMed ID: 10858434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of oxytocin receptors, but not arginine-vasopressin V1a receptors, in the ventral tegmental area of male Syrian hamsters is essential for the reward-like properties of social interactions.
    Song Z; Borland JM; Larkin TE; O'Malley M; Albers HE
    Psychoneuroendocrinology; 2016 Dec; 74():164-172. PubMed ID: 27632574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the pharmacological profiles of arginine vasopressin and oxytocin analogs at marmoset, macaque, and human vasopressin 1a receptor.
    Pierce ML; French JA; Murray TF
    Biomed Pharmacother; 2020 Jun; 126():110060. PubMed ID: 32145592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.